舒巴坦和氨苄西林在患脑膜炎婴幼儿脑脊液中的穿透情况。
Penetration of sulbactam and ampicillin into cerebrospinal fluid of infants and young children with meningitis.
作者信息
Foulds G, McBride T J, Knirsch A K, Rodriguez W J, Khan W N
机构信息
Central Research Division, Pfizer, Inc., Groton, Connecticut 06340.
出版信息
Antimicrob Agents Chemother. 1987 Nov;31(11):1703-5. doi: 10.1128/AAC.31.11.1703.
Abstract
Infusions of 50 mg of sulbactam per kg per day and 400 mg of ampicillin per kg per day in divided doses to infants and children with bacterial meningitis produced levels in cerebrospinal fluid approximately one-third those in serum. Concentrations in cerebrospinal fluid of 5.5 micrograms of sulbactam per ml and 16.0 micrograms of ampicillin per ml declined within a few days of therapy to 1.9 microgram of sulbactam per ml and 5.2 micrograms of ampicillin per ml.
摘要
对于患有细菌性脑膜炎的婴幼儿和儿童，每日每千克体重静脉输注50毫克舒巴坦和400毫克氨苄西林（分剂量给药）后，脑脊液中的药物浓度约为血清中的三分之一。治疗几天后，脑脊液中舒巴坦浓度从每毫升5.5微克降至每毫升1.9微克，氨苄西林浓度从每毫升16.0微克降至每毫升5.2微克。
相似文献
1
Penetration of sulbactam and ampicillin into cerebrospinal fluid of infants and young children with meningitis.
Antimicrob Agents Chemother. 1987 Nov;31(11):1703-5. doi: 10.1128/AAC.31.11.1703.
2
Penetration of sulbactam into the cerebrospinal fluid of patients with bacterial meningitis receiving ampicillin therapy.
Rev Infect Dis. 1986 Nov-Dec;8 Suppl 5:S612-6. doi: 10.1093/clinids/8.supplement_5.s612.
3
Sulbactam/ampicillin vs. chloramphenicol/ampicillin for the treatment of meningitis in infants and children.
Rev Infect Dis. 1986 Nov-Dec;8 Suppl 5:S620-9. doi: 10.1093/clinids/8.supplement_5.s620.
4
[Cerebrospinal fluid levels of sulbactam/ampicillin in rabbits with staphylococcal meningitis].
Jpn J Antibiot. 1989 Mar;42(3):594-7.
5
Use of ampicillin-sulbactam for treatment of experimental meningitis caused by a beta-lactamase-producing strain of Escherichia coli K-1.
Antimicrob Agents Chemother. 1991 Oct;35(10):2037-41. doi: 10.1128/AAC.35.10.2037.
6
Clinicopharmacological evaluation of amoxicillin and probenecid against bacterial meningitis.
Antimicrob Agents Chemother. 1979 Sep;16(3):346-52. doi: 10.1128/AAC.16.3.346.
7
Pharmacokinetics of sulbactam/ampicillin in humans: a review.
Rev Infect Dis. 1986 Nov-Dec;8 Suppl 5:S503-11. doi: 10.1093/clinids/8.supplement_5.503.
8
The penetration of broad-spectrum antibiotics into the cerebrospinal fluid.
Ann N Y Acad Sci. 1967 Sep 27;145(2):473-81. doi: 10.1111/j.1749-6632.1967.tb50247.x.
9
Pharmacokinetics of cefamandole and ampicillin in experimental meningitis.
Antimicrob Agents Chemother. 1979 Nov;16(5):584-8. doi: 10.1128/AAC.16.5.584.
10
[Factors of meningeal diffusion of amoxicillin and ampicillin at the acute phase of purulent meningitis in children].
Arch Fr Pediatr. 1985 Feb;42(2):129-32.
引用本文的文献
1
Central Nervous System Antimicrobial Exposure and Proposed Dosing for Anthrax Meningitis.
Clin Infect Dis. 2024 Jun 14;78(6):1451-1457. doi: 10.1093/cid/ciae093.
2
Ampicillin/Sulbactam Treatment Modulates NMDA Receptor NR2B Subunit and Attenuates Neuroinflammation and Alcohol Intake in Male High Alcohol Drinking Rats.
Biomolecules. 2020 Jul 10;10(7):1030. doi: 10.3390/biom10071030.
3
Drug concentrations in the serum and cerebrospinal fluid of patients treated with cefoperazone/sulbactam after craniotomy.
BMC Anesthesiol. 2015 Mar 13;15:33. doi: 10.1186/s12871-015-0012-1. eCollection 2015.
4
Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.
Paediatr Drugs. 2013 Apr;15(2):93-117. doi: 10.1007/s40272-013-0017-5.
5
Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.
Clin Microbiol Rev. 2010 Oct;23(4):858-83. doi: 10.1128/CMR.00007-10.
6
Ampicillin/sulbactam: current status in severe bacterial infections.
Drugs. 2007;67(13):1829-49. doi: 10.2165/00003495-200767130-00003.
7
Different ratios of the piperacillin-tazobactam combination for treatment of experimental meningitis due to Klebsiella pneumoniae producing the TEM-3 extended-spectrum beta-lactamase.
Antimicrob Agents Chemother. 1994 Feb;38(2):195-9. doi: 10.1128/AAC.38.2.195.
8
Evaluation of piperacillin-tazobactam in experimental meningitis caused by a beta-lactamase-producing strain of K1-positive Escherichia coli.
Antimicrob Agents Chemother. 1990 May;34(5):697-701. doi: 10.1128/AAC.34.5.697.
9
Brain abscess caused by Brucella abortus and Staphylococcus aureus in a child.
Infection. 1990 Nov-Dec;18(6):386-7. doi: 10.1007/BF01646416.
10
Use of ampicillin-sulbactam for treatment of experimental meningitis caused by a beta-lactamase-producing strain of Escherichia coli K-1.
Antimicrob Agents Chemother. 1991 Oct;35(10):2037-41. doi: 10.1128/AAC.35.10.2037.
本文引用的文献
1
Antimicrobial susceptibility of Haemophilus influenzae.
Antimicrob Agents Chemother. 1974 Nov;6(5):620-4. doi: 10.1128/AAC.6.5.620.
2
Increasing ampicillin-resistance rates in Hemophilus influenzae meningitis.
Am J Dis Child. 1984 Apr;138(4):366-9. doi: 10.1001/archpedi.1984.02140420032012.
3
Pharmacokinetics and bioavailability of sultamicillin estimated by high performance liquid chromatography.
J Antimicrob Chemother. 1983 May;11(5):435-45. doi: 10.1093/jac/11.5.435.
4
Pharmacokinetics of sulbactam in humans.
Antimicrob Agents Chemother. 1983 May;23(5):692-9. doi: 10.1128/AAC.23.5.692.
5
Comparative pharmacokinetics and tissue penetration of sulbactam and ampicillin after concurrent intravenous administration.
Antimicrob Agents Chemother. 1982 Apr;21(4):565-7. doi: 10.1128/AAC.21.4.565.
6
CP-45,899 in combination with penicillin or ampicillin against penicillin-resistant Staphylococcus, Haemophilus influenzae, and Bacteroides.
Antimicrob Agents Chemother. 1980 Apr;17(4):615-22. doi: 10.1128/AAC.17.4.615.
7
Clavulanic acid and CP-45,899: a comparison of their in vitro activity in combination with penicillins.
J Antimicrob Chemother. 1980 Mar;6(2):197-206. doi: 10.1093/jac/6.2.197.
8
Inhibition kinetics of three R-factor-mediated beta-lactamases by a new beta-lactam sulfone (CP 45899).
Biochim Biophys Acta. 1980 Feb 14;611(2):351-7. doi: 10.1016/0005-2744(80)90071-6.
9
Editorial: Should ampicillin be abandoned for treatment of Haemophilus influenzae disease?
JAMA. 1974 Jul 15;229(3):322-4.
10
Haemophilus influenzae type B resistant to ampicillin. A report of two cases.
JAMA. 1974 Jul 15;229(3):298-301.
Zotero 插件